VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free

Western Blot: VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free [NBP1-18646] - VEGFR2/KDR/Flk-1 Antibody (20I6) [NBP1-18646] - Recombinant human endogenous soluble VEGFR-2/KDR (esKDR) was produced in insect cells. Western blot was performed using our monoclonal anti-VEGFR-2 recognizing the soluble as well as the transmembrane form of KDR (left panal) and our new poyclonal antibody directed against the unique C-terminal end of the endogenous sKDR (CGRETILDHSAEAVGMP) recognizing solely the endogenous form but not sKDR (D7) and sKDR (D7)-Fc consisting of the full extraplasmatic domain. The endogenous sKDR generated by alternative splicing consists of the first 6 Ig-like loops with a unique c-terminal end.

Immunocytochemistry/Immunofluorescence: VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free [NBP1-18646] - HMEC-1 CRL-3243 cells, stained with 1:50 VEGFR2/KDR/Flk-1 antibody (NBP1-18645AF488) (green) and DAPI (blue). Image from verified customer review.

Flow Cytometry: VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free [NBP1-18646] - VEGFR2/KDR/Flk-1 Antibody (20I6) [NBP1-18646] - Analysis with primary human dermal lymphatic endothelial cells(HDLEC).

Immunocytochemistry/Immunofluorescence: VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free [NBP1-18646] - VEGFR2/KDR/Flk-1 Antibody (20I6) [NBP1-18646] - Staining (green) of VEGFR-2 (KDR) in primary human umbilical vein endothelial cells (HUVEC) with anti-human VEGFR-2 (Cl.4) (7,5ug/ml) and counter staining of nuclei with Dapi. As secondary antibody goat anti-mouse ALEXA Flour 488 (Dianova) was used 1:600.

• Reactivity: Hu
• Applications: WB, ELISA, Flow, ICC/IF, IHC, CyTOF-ready
• Clone: 20I6
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: Azide and BSA Free
• Concentration: LYOPH

VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free Summary

• Description: Clone #4 changed to 20I6 for a more unique identifier.
• Immunogen: Recombinant human soluble extracellular KDR (D7)
• Marker: Endothelial Cell Marker
• Specificity: The monoclonal antibody will detect native human VEGFR-2/KDR in ELISA experiments and on the surface of different human cell types.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: KDR
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • ELISA 1-10 ug/ml
  • Flow Cytometry 2-5 ug/ml
  • Immunocytochemistry/ Immunofluorescence 1-2 ug/ml
  • Immunohistochemistry 1:10-1:500
  • Western Blot 2-5 ug/ml

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: No Preservative
• Concentration: LYOPH
• Purity: Protein G purified
• Reconstitution Instructions: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml. Please note the sample size of this product will be provided in reconstituted liquid form.

Alternate Names for VEGFR2/KDR/Flk-1 Antibody (20I6) - Azide and BSA Free

• CD309 antigen
• CD309
• EC 2.7.10
• EC 2.7.10.1
• Fetal liver kinase 1
• fetal liver kinase-1
• Flk1
• Flk-1
• FLK1tyrosine kinase growth factor receptor
• KDR
• kinase insert domain receptor (a type III receptor tyrosine kinase)
• Kinase insert domain receptor
• KRD1
• Ly73
• Protein-tyrosine kinase receptor flk-1
• soluble VEGFR2
• vascular endothelial growth factor receptor 2
• VEGF R2
• VEGFR
• VEGFR2
• VEGFR-2

Background

VEGF receptor 2 is a member of a receptor tyrosine kinase family whose activation plays an essential role in a large number of biological processes such as embryonic development, wound healing, cell proliferation, migration and differentiation. Like other growth factor receptors, upon ligand binding VEGF receptor 2 dimerises and is autophosphorylated on multiple tyrosine residues. These sites can be involved in the regulation of kinase activity or serve as binding sites for SH2 and phosphotyrosine binding containing signalling proteins. Phosphorylation of Tyrosines 1054 and 1059 in the activation loop is required for activation of VEGF receptor 2 and its intrinsic tyrosine kinase activity. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for VEGFR2/KDR/Flk-1 Antibody (NBP1-18646)(1)

Publication using NBP1-18646

• Halbert D, Domenyuk V, Spetzler D et al. Aptamers and uses thereof United States Patent Application US 9958448 B2 2018-01-01

Bioinformatics

• Gene Symbol: KDR
• Entrez:
  • 3791(Human)